EGFR and non-small cell lung carcinoma: Small molecule tyrosine kinase inhibitors (TKIs) targeting EGFR, including first/second-generation TKIs (gefitinib, erlotinib, and afatanib) and third-generation TKIs (osimertinib), have been extensively employed in the treatment of NSCLC patients with EGFR-sensitive mutations and have exhibited favorable outcomes [4–7].